Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.50 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11357364 | 0.85 | LMNA (0.46) | KMT2A | |
| SCHEMBL3824575 | 0.82 | MAOB (0.54) | SMPD1KMT2A | |
| SCHEMBL3824878 | 0.82 | MAOB (0.54) | SMPD1KMT2A | |
| SCHEMBL3829423 | 0.82 | MAOB (0.54) | SMPD1KMT2A | |
| SCHEMBL3823699 | 0.82 | CYP3A4 (0.46) | — | |
| SCHEMBL3830321 | 0.82 | CYP3A4 (0.46) | — | |
| SCHEMBL3826804 | 0.82 | CYP3A4 (0.46) | — | |
| SCHEMBL14214411 | 0.81 | OPRK1 (0.42) | SMPD1THRBKMT2A | |
| SCHEMBL14214412 | 0.81 | OPRK1 (0.42) | SMPD1THRBKMT2A | |
| SCHEMBL13846076 | 0.81 | LMNA (0.45) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080114005-A1 | 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114005-A1 | 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity | PPARA, PPARD, PPARG | PLA2G4B 604/4885SMPD1 1943/4885THRB 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.